Literature DB >> 19558608

Development and content validity of a gastroparesis cardinal symptom index daily diary.

D A Revicki1, M Camilleri, B Kuo, N J Norton, L Murray, A Palsgrove, H P Parkman.   

Abstract

BACKGROUND: The Gastroparesis Cardinal Symptom Index (GCSI) is a patient-reported outcome for gastroparesis using a two-week recall period. To minimize potential patient recall effects, a daily diary version of the GCSI (GCSI-DD) was developed. AIMS: To evaluate the content validity of GCSI-DD for the symptoms in patients with documented gastroparesis, to capture symptom variability over time and to compare responses of this GCSI-DD to the original GCSI.
METHODS: In gastroparesis adults with delayed gastric emptying, cognitive debriefing interviews were conducted to elicit their perspective on relevant symptoms of gastroparesis and relevant recall periods and to evaluate patient understanding of GCSI-DD. Patients completed the GCSI-DD daily over a 2-week period and completed the GCSI at baseline and the 2-week follow-up visit.
RESULTS: Twelve gastroparesis patients, of whom five were diabetic and nine women, reported nausea (100%), vomiting (100%), stomach fullness (75%), bloating (58%) and loss of appetite (50%) were important symptoms. All patients understood diary instructions and item content and reported that the diary captured their gastroparesis symptom experience; 83% considered response scales adequate. There was significant daily variability in GCSI-DD scores. Mean GCSI-DD subscale and total scores over 2 weeks correlated strongly (all r > 0.90) with GCSI scores at 2-week follow-up.
CONCLUSIONS: The GCSI-DD includes symptoms relevant to patients with gastroparesis, captures daily variability of those symptoms and has psychometric properties consistent with a good patient-reported outcome endpoint for gastroparesis clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19558608     DOI: 10.1111/j.1365-2036.2009.04078.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  41 in total

Review 1.  Idiopathic gastroparesis.

Authors:  Henry P Parkman
Journal:  Gastroenterol Clin North Am       Date:  2014-12-24       Impact factor: 3.806

Review 2.  Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years.

Authors:  Purna Kashyap; Gianrico Farrugia
Journal:  Gut       Date:  2010-09-25       Impact factor: 23.059

Review 3.  Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting.

Authors:  H P Parkman; M Camilleri; G Farrugia; R W McCallum; A E Bharucha; E A Mayer; J F Tack; R Spiller; M Horowitz; A I Vinik; J J Galligan; P J Pasricha; B Kuo; L A Szarka; L Marciani; K Jones; C R Parrish; P Sandroni; T Abell; T Ordog; W Hasler; K L Koch; K Sanders; N J Norton; F Hamilton
Journal:  Neurogastroenterol Motil       Date:  2009-12-09       Impact factor: 3.598

Review 4.  Gastroparesis: pathogenesis, diagnosis and management.

Authors:  William L Hasler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-19       Impact factor: 46.802

5.  Multi-Dimensional Gastrointestinal Symptom Severity Index: Validation of a Brief GI Symptom Assessment Tool.

Authors:  Michael D Crowell; Sarah B Umar; Brian E Lacy; Michael P Jones; John K DiBaise; Nicholas J Talley
Journal:  Dig Dis Sci       Date:  2015-04-05       Impact factor: 3.199

Review 6.  Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.

Authors:  Nelson Valentin; Andres Acosta; Michael Camilleri
Journal:  Expert Opin Investig Drugs       Date:  2015-06       Impact factor: 6.206

Review 7.  Treatment of refractory diabetic gastroparesis: Western medicine and traditional Chinese medicine therapies.

Authors:  Bing Pang; Qiang Zhou; Jun-Ling Li; Lin-Hua Zhao; Xiao-Lin Tong
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

8.  Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution.

Authors:  John H Rodriguez; Ivy N Haskins; Andrew T Strong; Ryan L Plescia; Matthew T Allemang; Robert S Butler; Michael S Cline; Kevin El-Hayek; Jeffrey L Ponsky; Matthew D Kroh
Journal:  Surg Endosc       Date:  2017-05-31       Impact factor: 4.584

9.  GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist.

Authors:  Subhankar Chakraborty; Magnus Halland; Duane Burton; Anshuman Desai; Bridget Neja; Phillip Low; Wolfgang Singer; Michael Camilleri; Alan R Zinsmeister; Adil E Bharucha
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

10.  Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders.

Authors:  Pankaj J Pasricha; Katherine P Yates; Irene Sarosiek; Richard W McCallum; Thomas L Abell; Kenneth L Koch; Linda Anh B Nguyen; William J Snape; William L Hasler; John O Clarke; Sameer Dhalla; Ellen M Stein; Linda A Lee; Laura A Miriel; Mark L Van Natta; Madhusudan Grover; Gianrico Farrugia; James Tonascia; Frank A Hamilton; Henry P Parkman
Journal:  Gastroenterology       Date:  2017-10-28       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.